Tempus AI inks deals with AstraZeneca, Pathos for $200M data licensing, $35M fee for oncology AI model

Tempus AI, Inc.

AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.
Tempus and Pathos sign Order Form: Pathos pays $200M data license fees over 3 years ($50M upfront); Tempus receives license to use model.
Pathos may pay up to 50% of data license fees in shares of Pathos Series D Preferred Stock at its discretion.
Tempus pays Pathos $35M in consideration for Pathos' commitments under the Pathos Master Agreement.
Syndicate led by AstraZeneca will execute stock purchase agreement with Pathos in preferred stock financing round.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.